BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 23569313)

  • 1. Vemurafenib as neoadjuvant treatment for unresectable regional metastatic melanoma.
    Koers K; Francken AB; Haanen JB; Woerdeman LA; van der Hage JA
    J Clin Oncol; 2013 Jun; 31(16):e251-3. PubMed ID: 23569313
    [No Abstract]   [Full Text] [Related]  

  • 2. Vemurafenib therapy for stage IV melanoma with V600G-mutation.
    Lang N; Weisser A; Enk A; Hassel JC
    J Dtsch Dermatol Ges; 2013 Dec; 11(12):1198-9. PubMed ID: 24016000
    [No Abstract]   [Full Text] [Related]  

  • 3. Inoperable bulky melanoma responds to neoadjuvant therapy with vemurafenib.
    Fadaki N; Cardona-Huerta S; Martineau L; Thummala S; Cheng ST; Bunker SR; Garcia-Kennedy R; Wang W; Minor D; Kashani-Sabet M; Leong SP
    BMJ Case Rep; 2012 Oct; 2012():. PubMed ID: 23093505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [BRAF mutation detection in metastatic melanoma].
    Dietel M; Enk A; Lehmann A; Bauer J; Garbe C; Kellner U; Kirchner T; Jung A; Kreipe H; Merkelbach-Bruse S; Büttner R; Rüschoff J; Schlake W; Schirmacher P; Penzel R; Stadler R
    Pathologe; 2012 Jul; 33(4):352-6. PubMed ID: 22692278
    [No Abstract]   [Full Text] [Related]  

  • 5. BRAF(V600) mutation levels predict response to vemurafenib in metastatic melanoma.
    Lebbé C; How-Kit A; Battistella M; Sadoux A; Podgorniak MP; Sidina I; Pages C; Roux J; Porcher R; Tost J; Mourah S
    Melanoma Res; 2014 Aug; 24(4):415-8. PubMed ID: 24933605
    [No Abstract]   [Full Text] [Related]  

  • 6. Vemurafenib as a neoadjuvant therapy in advanced melanoma: local tumour control, but no prevention of metastatic relapse.
    Tauber M; Pages C; La Selva R; Schneider P; Chardin J; Osio A; Mourah S; Culine S; Vercellino L; Bagot M; Lebbé C
    Eur J Dermatol; 2013; 23(5):702-3. PubMed ID: 24135270
    [No Abstract]   [Full Text] [Related]  

  • 7. Successful treatment with vemurafenib in BRAF V600K-positive cerebral melanoma metastasis.
    Forschner A; Niessner H; Bauer J; Bender B; Garbe C; Meier F
    JAMA Dermatol; 2013 May; 149(5):642-4. PubMed ID: 23677116
    [No Abstract]   [Full Text] [Related]  

  • 8. Vemurafenib: a guide to its use in unresectable or metastatic melanoma.
    Keating GM; Lyseng-Williamson KA
    Am J Clin Dermatol; 2013 Feb; 14(1):65-9. PubMed ID: 23329082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRAF-Targeted Therapy to Treat Superior Vena Cava Syndrome in a Patient With Metastatic Cancer.
    Mesko SM; Rosenthal KJ; Boasberg PD; Hamid O
    J Clin Oncol; 2015 Sep; 33(25):e101-3. PubMed ID: 24711550
    [No Abstract]   [Full Text] [Related]  

  • 10. Cutaneous manifestations of vemurafenib therapy for metastatic melanoma.
    Owen JL; Lopez IE; Desai SR
    J Drugs Dermatol; 2015 May; 14(5):509-10. PubMed ID: 25942671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapidly metastasizing malignant melanoma characterized by a rare BRAF mutation not responding to vemurafenib.
    Starz H; Gutschi M; Welzel J; Haas C
    J Dtsch Dermatol Ges; 2014 Feb; 12(2):151-4. PubMed ID: 24238398
    [No Abstract]   [Full Text] [Related]  

  • 12. Absent response of intracranial melanoma metastases harboring BRAF V600E sequence variation to vemurafenib.
    D'Alonzo D; Glatz K
    Mayo Clin Proc; 2013 Dec; 88(12):e151-2. PubMed ID: 24290130
    [No Abstract]   [Full Text] [Related]  

  • 13. Vemurafenib: in unresectable or metastatic melanoma.
    Keating GM
    BioDrugs; 2012 Oct; 26(5):325-34. PubMed ID: 22946753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment of metastatic melanoma with BRAF inhibitors].
    Hafner C
    Hautarzt; 2011 Sep; 62(9):696-8. PubMed ID: 21863388
    [No Abstract]   [Full Text] [Related]  

  • 15. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.
    Larkin J; Del Vecchio M; Ascierto PA; Krajsova I; Schachter J; Neyns B; Espinosa E; Garbe C; Sileni VC; Gogas H; Miller WH; Mandalà M; Hospers GA; Arance A; Queirolo P; Hauschild A; Brown MP; Mitchell L; Veronese L; Blank CU
    Lancet Oncol; 2014 Apr; 15(4):436-44. PubMed ID: 24582505
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regression of orbital and choroidal metastases from melanoma after treatment with vemurafenib.
    Ngo E; Hutchins LF; Gardner JM; Uwaydat SH
    Can J Ophthalmol; 2014 Apr; 49(2):e49-52. PubMed ID: 24767240
    [No Abstract]   [Full Text] [Related]  

  • 17. Induction vemurafenib followed by consolidative radiation therapy for surgically incurable melanoma.
    Seeley AR; De Los Santos JF; Conry RM
    Melanoma Res; 2015 Jun; 25(3):246-51. PubMed ID: 25746037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRAF mutation-positive folliculotropic metastatic melanoma.
    Brick KE; Halling KC; Khan YK; Peters MS
    Am J Dermatopathol; 2013 Jul; 35(5):609-12. PubMed ID: 23715079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Strides in melanoma announced: maximizing value comes next.
    Tuma RS
    J Natl Cancer Inst; 2011 Jul; 103(13):997-9. PubMed ID: 21693727
    [No Abstract]   [Full Text] [Related]  

  • 20. Vemurafenib-induced bilateral facial palsy.
    Shailesh FN; Singh M; Tiwari U; Hutchins LF
    J Postgrad Med; 2014; 60(2):187-8. PubMed ID: 24823520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.